Our results strongly support that BiP levels in blood or in bronchoalveolar fluid can be used as an early severity biomarker of risk of pneumonia in COVID-19 and other respiratory inflammatory diseases. This evidence concerns the gene HSPA5 and susceptibility to pneumonia measurement.